- Previous Close
11.66 - Open
11.73 - Bid 11.63 x --
- Ask 11.64 x --
- Day's Range
11.54 - 11.90 - 52 Week Range
9.03 - 19.78 - Volume
1,843,302 - Avg. Volume
3,391,763 - Market Cap (intraday)
4.84B - Beta (5Y Monthly) 0.83
- PE Ratio (TTM)
25.28 - EPS (TTM)
0.46 - Earnings Date --
- Forward Dividend & Yield 0.05 (0.41%)
- Ex-Dividend Date May 31, 2024
- 1y Target Est
--
Novogene Co., Ltd. provides genomic services and solutions worldwide. The company offers genomic solutions, such as human genome sequencing, gene regulation, single cell sequencing, animal and plant solutions, and microbial genome sequencing; and cancer genomic profiling, whole exome sequencing, and FFPE RNA sequencing, as well as clinical-grade whole exome sequencing services. It also provides NovoFocus CR, a gene coverage for hereditary cancer screening; and NovoNeoantigen, a bioinformatics pipeline for the identification of cancer neoantigens with whole exome sequencing and whole transcriptome sequencing data from paired tumor-normal samples. The company was founded in 2011 and is headquartered in Beijing, China.
www.novogene.comRecent News: 688315.SS
View MorePerformance Overview: 688315.SS
Trailing total returns as of 1/16/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 688315.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 688315.SS
View MoreValuation Measures
Market Cap
4.85B
Enterprise Value
3.64B
Trailing P/E
25.35
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.27
Price/Book (mrq)
2.00
Enterprise Value/Revenue
1.74
Enterprise Value/EBITDA
15.97
Financial Highlights
Profitability and Income Statement
Profit Margin
8.95%
Return on Assets (ttm)
3.51%
Return on Equity (ttm)
8.46%
Revenue (ttm)
2.09B
Net Income Avi to Common (ttm)
187.24M
Diluted EPS (ttm)
0.46
Balance Sheet and Cash Flow
Total Cash (mrq)
1.25B
Total Debt/Equity (mrq)
1.50%
Levered Free Cash Flow (ttm)
167.37M